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“Educate. Inspire. Connect.” Those are the missions of the annual Lindau Nobel Laureate Meeting. Since 1951, 
Nobel laureates have gathered in the picturesque 
town of Lindau, Germany, to discuss science. 
Starting in 1953, the meetings incorporated 
young scientists from across the world to instill 
in them enthusiasm for and knowledge of 
science, while also providing an atmosphere 
for collaboration. From 29 June to 4 July 2014, 
approximately 600 young scientists representing 
nearly 80 countries gathered in this small town 
on the shores of Lake Constance and in view of 
the snow-capped Swiss Alps to directly inter-
act with 37 Nobel laureates. Given this year’s 
theme of Physiology and Medicine, it was a great 
privilege to attend this meeting as a young der-
matologic investigator. Although it was a gen-
eral scientific meeting, many of the insights into 
research, publication, funding, and professional 
development offered by the Nobel laureates are 
relevant to dermatology. My goal in this Editorial 
is to share these insights and to increase aware-
ness of this unique scientific meeting.
The immune system
The immune system underlies many dermatolog-
ic diseases. Jules Hoffmann (2011 Nobel Prize in 
Physiology or Medicine) described his research 
on the activation of innate immunity in insects, 
which led to the discovery of the Toll gene and 
how recognition of fungi and Gram-positive 
bacteria generates host antimicrobial defenses. 
He further examined the role of the Drosophila 
immune deficiency pathway in recognizing 
Gram-negative bacteria. He explained that the 
hallmark of the two pathways is activation of 
NF-κB followed by control of gene expression. 
His career studying insects was influenced by 
two observations: insects represent 80% of living 
species and insects are resistant to infection.
Bruce Beutler, who shared the Nobel Prize 
with Hoffmann, detailed how his work on 
lipopolysaccharide led to the identification 
of its receptor, Toll-like receptor 4, as a sensor 
for mammalian microbial infection. He then 
described his current research using “forward 
genetics”: he generates numerous random muta-
tions in mice to create a phenotype of deficient 
or altered immune system function and then 
works to elucidate the molecular basis of the 
phenotype. His goal is to understand all genes 
needed for proper immune function.
Robert Huber (1988 Nobel Prize in 
Chemistry) discussed the structure and function 
of the proteasome in protein degradation, focus-
ing on the immunoproteasome. Characterized 
by incorporation of inducible factors LMP2, 
MECL-1, and LMP7, the immunoproteasome 
is increasingly becoming a target for drug inhi-
bition. For example, LMP7 inhibitors have 
decreased differentiation of T helper cell types 1 
and 17 in experimental autoimmune encephalo-
myelitis and are being studied in a mouse model 
of multiple sclerosis.
Infectious disease
Hand in hand with the immune system are infec-
tious agents. HIV and tuberculosis were two hot 
topics addressed by several Nobel laureates, 
with a strong emphasis placed on the need for 
drug development for both diseases. Françoise 
Barré-Sinoussi (2008 Nobel Prize in Physiology 
or Medicine) recounted her background in retro-
viruses and the opportunity this training afforded 
her when discovering HIV as a cause of AIDS. 
She stressed the importance of investigating the 
mechanisms by which HIV persists in the human 
body and the reservoirs it uses. Rolf Zinkernagel 
(1996 Nobel Prize in Physiology or Medicine) 
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translated his experience studying cytotoxic T-cell recogni-
tion of infected cells into a hypothesis as to why vaccines 
against HIV or tuberculosis are difficult to achieve. He chal-
lenged our understanding of “immunologic memory” and 
discussed the important role of preexisting neutralizing anti-
bodies and preactivated T cells in robust immunity.
Barry Marshall (2005 Nobel Prize in Physiology or 
Medicine) entertained attendees with his research on 
Helicobacter pylori and its link to gastritis and peptic ulcer 
disease. After recounting self-administration of H. pylori to 
aid in his discovery, Marshall reminded young researchers 
of the importance of internal review boards and the safety 
protocols they establish. Connecting the immune system 
with infectious disease and dermatology, Marshall discussed 
evidence suggesting that childhood infection with H. pylori 
protects against atopic diseases, including asthma and atopic 
dermatitis. He believes that more research into a possible 
link between H. pylori and regulation of the immune system 
in atopy is needed; a recent longitudinal birth cohort study 
supports this association (Amberbir et al., 2014).
Hamilton Smith (1978 Nobel Prize in Physiology or 
Medicine) discovered type II restriction enzymes, but lectured 
on his fascinating work in the field of “synthetic biology.” He 
is creating an engineered Mycoplasma organism by chemi-
cally synthesizing a genome reduced to only its essential 
genes. Peter Agre (2003 Nobel Prize in Chemistry) described 
his personal development as an investigator and his discovery 
of aquaporins. Aquaporin research ultimately led him to study 
malaria, a parasitic disease for which Agre emphasized the 
need for more investigation and drug development. 
Cancer
Several Nobel laureates discussed their research on various 
types of cancer. J. Michael Bishop (1989 Nobel Prize 
in Physiology or Medicine) outlined how the malfunc-
tion of genes leads to cancer through gain-of-function 
(protooncogene) or loss-of-function (tumor suppressor genes) 
mutations. He provided a history of several milestones in 
cancer research, including Ernest Kennaway’s identifica-
tion of carcinogens in coal tar and James Cleaver’s work 
showing that deficiencies in DNA-repair enzymes underlie 
the accumulation of UV-induced DNA damage in xeroderma 
pigmentosum. Bishop was driven by the question of how 
Rous sarcoma virus transformed cells, leading to the observa-
tion that viral DNA can be integrated into the host cell.
Because dermatologists face the consequences of 
human papillomavirus (HPV) infection every day in the 
clinic, the discussion by Harald zur Hausen (2008 Nobel 
Prize in Physiology or Medicine) of the role of HPV 
infection in cervical cancer as well as the impact HPV 
vaccines will play in decreasing HPV-induced disease was 
of particular interest. For dermatologists, these vaccines 
will be beneficial in both male and female populations for 
reducing genital warts and cancers. Martin Evans (2007 
Nobel Prize in Physiology or Medicine) described work 
on malignant cells, particularly mouse terato carcinomas, 
which led to an excellent system for identifying and 
isolating embryonic stem cells.
Elizabeth Blackburn (2009 Nobel Prize in Physiology 
or Medicine) approached cancer from the “end,” describ-
ing her discovery of telomerase in maintaining telomeres. 
Telomerase mutations are associated with dyskeratosis con-
genita, and Blackburn emphasized that, whereas some can-
cers have too little telomerase activity, melanoma can have 
too much. About 400 genes contribute to the balance of telo-
mere length, with telomerase levels being crucial. Her recent 
work on the epidemiology of telomere length has yielded 
interesting observations, including a dose-dependent reduc-
tion of telomere length in smokers and a direct correlation 
between level of education and longer telomeres.
Translational research
This year’s lectures unintentionally developed a recurrent 
theme: translate basic science discoveries into either applica-
tions or medical advances that benefit mankind. Ironically, the 
Nobel laureates emphasized the need for more basic-science 
research and encouraged young researchers to tackle funda-
mental problems. Yet the amount of translational research being 
conducted by these scientists led me to conclude, “Excellent 
science will itself generate opportunities for translational appli-
cations.” Thomas Steitz and Ada Yonath (2009 Nobel Prize in 
Chemistry) exemplified this notion because their years of fun-
damental structural studies of the ribosome are now a plat-
form for the development of new antimicrobial agents and 
understanding antibiotic resistance. Aptly, the final panel 
discussion was entitled “Science for the Benefit of Mankind.”
Publication and funding
All the Nobel laureates agreed on the current state of publica-
tion and funding mechanisms in science—namely, they think 
major reform is needed. Randy Schekman (2013 Nobel Prize 
in Physiology or Medicine) stressed to young researchers that 
it is the quality of the science that matters, not impact fac-
tor or journal title. He, along with many others, believes that 
the impact factor is a flawed metric that “devalues scholarly 
achievement” and receives improper emphasis in the fund-
ing process. Schekman encouraged all researchers to read and 
sign the “San Francisco Declaration on Research Assessment,” 
available online (http://am.ascb.org/dora). Interestingly, many 
of the Nobel laureates had saved old rejection letters from var-
ious journals and showed them at the meeting, the point being 
that their own groundbreaking research was at times rejected 
or dismissed. They offered this as encouragement to young 
researchers that, in time, excellent science prevails.
Career development
The goal of the Lindau Nobel Laureate Meeting is to inspire 
young scientists from across the world; with that inspira-
tion comes much-needed practical advice for those begin-
ning their careers. Oliver Smithies (2007 Nobel Prize in 
Physiology or Medicine) offered five basic pearls of wis-
dom for young researchers: (i) choose excellent mentors; (ii) 
read, read, and read some more; (iii) enjoy what you do (“It 
is pointless to do something you don’t enjoy”); (iv) learn to 
do “good science” first, because this matters more than what 




Because a gathering of 37 Nobel laureates for scientif-
ic discussions is worthy of celebration, the 64th Lindau 
Nobel Laureate Meeting enriched its scientific content 
with several unique cultural experiences. The opening 
ceremony treated the laureates and young scientists to a 
special concert by the Vienna String Quartet of the Vienna 
Philharmonic Orchestra. The following night, Australian 
participants—who highlighted their country’s commitment 
to research excellence—hosted an “International Day” 
dinner where Genevieve Lacey provided a masterly per-
formance on the recorder and Brian Schmidt (2011 Nobel 
Prize in Physics) served Australian wine from his personal 
vineyard. The last evening of the meeting was celebrated 
as a “Bavarian Evening,” courtesy of the Elite Network of 
Bavaria and the Free State of Bavaria; many put on their 
lederhosen and enjoyed German dance, food, and drink. 
On the final day of the meeting, the State of Baden-
Württemberg and the Lennart Bernadotte Foundation 
invited participants to enjoy a boat cruise to the flowering 
island of Mainau (http://www.mainau.de/home.html), also 
located on Lake Constance. Countess Bettina Bernadotte, 
president of the Council for the Lindau Nobel Laureate 
Meetings, concluded the meeting from Mainau's castle 
steps while encouraging collaboration among researchers 
and a commitment to excellent science.
How young dermatologists can participate in a Lindau Meeting
It is my hope that more young dermatologists early in their 
training can have the privilege to attend a Lindau Nobel 
Laureate Meeting. Senior dermatology faculty should 
encourage their promising students, residents, and young 
faculty to participate in this unique scientific gathering. 
Guidance for the application process can be found online 
(http://www.lindau-nobel.org/FAQ_Young_Researchers.
AxCMS); application requires a nomination from either a 
Nobel laureate or an Academic Partner of the Lindau Meeting. 
Numerous videos of the lectures can be viewed at the meeting’s 
website (http://www.mediatheque.lindau-nobel.org).
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